BIOSGN.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$1M	-99.5%	$-1.10	$-1.10–$-1.10	—	1
2027	$259M	+18407.1%	$10.95	$10.95–$10.95	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 5 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-02-10	$-0.01	$-0.58	-5211.4%
2025-11-19	$-0.22	$-0.57	-159.0%
2025-08-20	$-0.22	$-0.51	-135.0%
2025-05-21	$-0.22	$-0.02	+90.9%
2025-03-05	$-0.22	$-0.02	+90.9%

DCF fair valuemodel estimate

Intrinsic value

$0.66

Price

$0.55

Implied upside

+21%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
BIOSGN.STBiosergen AB	$0.55	+0.92%	$12M	—
ACTI.STActive Biotech AB	$3.98	-0.62%	$105M	—
ARCOMA.STArcoma AB	$7.96	-4.10%	$114M	—
BIOVIC-B.STBiovica International AB (publ)	$0.30	-0.97%	$85M	—
CMOTEC-B.STScandinavian ChemoTech AB (publ)	$3.67

Biosergen AB

Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.

biosergen.net

Employees: 1
IPO / List date: Jun 24, 2021
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds BIOSGN.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in BIOSGN.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded BIOSGN.ST yet.